Maintenance rituximab failed to prolong progression or improve survival compared with observation in an older group of patients with mantle cell lymphoma who underwent induction therapy with bendamustine/rituximab.
PILLAR-2 failed to meet its primary endpoint of improved disease-free survival (DFS) with adjuvant everolimus in patients with poor-risk DLBCL. However, trends favoring everolimus for overall survival and lymphoma-specific survival and for DFS in selected subgroups were observed.
Addition of daratumumab to bortezomib and dexamethasone reduced the risk of disease progression or death by 61% in patients with relapsed/refractory multiple myeloma. Addition of the drug doubled rates of VGPR and CR, and it was associated with no cumulative toxicities.
CAR T-cell therapy could offer an exciting new treatment option for patients with relapsed or refractory ALL. However, many questions remain, including how to reduce toxicity associated with these therapies and select patient groups. Three clinical trials start to give answers.
Cancer affects everyone, and the impact of the disease extends beyond the patient to those close to them. Himself a cancer survivor, Chicago Cubs first baseman Anthony Rizzo founded the Anthony Rizzo Family Foundation to raise money to support families fighting cancer and for cancer research.
Significant gaps exist in end-of-life outcomes in hematologic oncology compared to solid-tumor oncology. Dr. David Hui and colleagues discuss possible reasons why, and the steps that can be taken to bridge these gaps.